Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy

Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease

(2013) Muriel Noetzli et al.   CLINICAL PHARMACOKINETICS

High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines

(2013) Jeffrey L. Cummings et al.   CNS Neuroscience & Therapeutics

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

(2011) Marwan Sabbagh et al.   BMC Neurology

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

EFNS guidelines for the diagnosis and management of Alzheimer’s disease

(2010) J. Hort et al.   EUROPEAN JOURNAL OF NEUROLOGY

Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-  in a Mouse Model of Alzheimer's Disease

(2010) A. M. S. Hartz et al.   MOLECULAR PHARMACOLOGY

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

(2009) Rachelle S Doody et al.   DRUGS & AGING